Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

, rater-blinded study that will compare alemtuzumab to Rebif(R) as first-line therapy for patients with relapsing-remitting multiple sclerosis (MS). The second Phase 3 study, CARE-MS II, also has begun and will enroll patients who have continued to experience relapse episodes while on currently available disease-modifying therapies.

Phase 2 Trial Design

The phase 2 trial randomized 334 patients with active relapsing-remitting multiple sclerosis at 49 medical centers in Europe and the United States. Patients in the trial were treated with alemtuzumab at one of two doses (12 or 24/mg per day intravenously for five days at initial treatment, and three days of re-treatment after 12 months with an option to treat again at 24 months), or interferon beta-1a (44 mcg administered by subcutaneous injection three times per week, as indicated in its product label).

The randomized trial compared the efficacy of alemtuzumab with interferon beta-1a using two primary endpoints: the rate of relapse of MS symptoms, and the time to Sustained Accumulation of Disability over six months as measured by Expanded Disability Status Scale [EDSS]. Efficacy assessments were made by independent neurologists blinded to therapy.

Alemtuzumab is an investigational drug for the treatment of MS and must not be used outside of a formal clinical trial setting in MS patients. Physicians or patients seeking additional information about the recently-initiated CARE-MS I Phase 3 trial should contact Genzyme Medical Information at 1-800-745-4447, option 2 in the United States, + 31 35 6991499 in Europe, or visit http://www.clinicaltrials.gov.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, debilitating disease in which the immune system attacks the person's brain and spinal cord. The disease causes a wide range of symptoms including fatigue, difficulty walking, numbness, and vision problems, and can pr
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  The International Trade Commission (ITC) issued its final ... Medical. In a notice issued on December 23, the ITC ... on its humidifier was invalid. BMC President, ... are very excited with the ITC,s decision in this case. ... taken since the very beginning on the key patents in ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... Pa., April 16 ViroPharma Incorporated,(Nasdaq: VPHM ... a,division of Wyeth (NYSE: WYE ), have ... previously announced safety issue that emerged in the,ongoing ... "Clearly, this is a disappointing outcome for ...
... State Funding Led to Important Clinical Trials, ... agency overstated and hyped the importance of its ... treat a severe blood disorder,Consumer Watchdog said today, ... support publicly funded stem cell,research., Last week ...
Cached Medicine Technology:ViroPharma Announces Discontinuation of HCV-796 Development 2California Stem Cell Agency Exaggerated Its Role in Funding Key Research 2
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... complex chronic illnesses can receive effective, less expensive care from ... access to a team of dedicated health care professionals, a ... seriously ill and need either hospitalization or a trip to ... medical home clinic at the University of Texas in Houston ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate ... Today, the business has introduced its new collection of ... promotion. , The new prom outfits are guaranteed to ... lover. They are specially designed for 2015. Anyone who ... should visit its website before Jan. 26, 2015, the ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... CHAPEL HILL, N.C., Nov. 2 With ... the manufacturing environment, best-in-class,companies continue to focus ... internal and external customer relationships. In reviewing,the ... more,than three-quarters of the benchmark class posts ...
... 2 Addressing more than,100 cardiologists and other ... and CEO, set out four critical priorities for,improving ... at,Schering-Plough,s fourth annual Cardiovascular Summit in advance of ... In his speech, Hassan emphasized the potential for ...
... Hair to Help ... Women with Cancer, CINCINNATI, Nov. 2 Two-time Oscar winner,Hilary ... of support for women with cancer. This national campaign,encourages people to ... create free wigs for women who have lost their hair due ...
... Recent outbreaks of,antibiotic-resistant Staphylococcus aureus, more commonly known as ... healthy people,can carry on the skin or nose, it is ... the skin, in the blood, in the bones and,in the ... of antibiotics.,While most of these infections are minor, some however, ...
... Icon Supports Bargaining for Improved Patient Care, HUNTINGTON ... and co-founder of the United Farm Workers of,America, will ... Park for a walkthrough to shed light on patient ... year, caregivers have been seeking a new contract at,the ...
... Technique just as effective in patients under 60, study finds ... known as brachytherapy, are just as effective for treating prostate ... older men, a new study finds. , Brachytherapy is ... placed in the prostate to kill cancer cells. Recovery time ...
Cached Medicine News:Health News:Manufacturing Organizations Identify Efficiencies in Credit and Collections Functions 2Health News:Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 3Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 4Health News:Radiation Seed Treatment Helps Younger Men Fight Prostate Cancer 2
... eNclose Anastomosis Assist Device ... obviate the need for ... aorta. The enclose device ... with a stable, bloodless ...
15mm Open Blades, 30mm Maximum Blade Spread; in Titanium....
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: